PhRMA-backed lobbying blocks 'most favored nation' drug pricing by end of 2026

Pharmaceutical industry leaders oppose Trump’s proposal for a 'most favored nation' drug pricing policy, citing potential market disruptions and care rationing. Given Republican opposition and industry lobbying, Congress is unlikely to pass the policy.

Implied probability (Yes)

80%